Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 23 Jun 2025 08:00 CEST |
NAVAMEDIC | Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue | 20103015 Pharmaceuticals | Inside information |
| 04 Jun 2025 10:29 CEST |
NAVAMEDIC | Navamedic ASA: Minutes of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 May 2025 14:35 CEST |
NAVAMEDIC | Navamedic ASA: Notice of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 May 2025 10:56 CEST |
NAVAMEDIC | Navamedic ASA launches Eroxon® in Denmark | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 30 Apr 2025 19:42 CEST |
NAVAMEDIC | Navamedic ASA: Annual Report 2024 | 20103015 Pharmaceuticals | Annual financial and audit Reports |
| 30 Apr 2025 07:00 CEST |
NAVAMEDIC | Navamedic Q1 2025: Sterk start på året og godt posisjonert for fremtidig vekst | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 30 Apr 2025 07:00 CEST |
NAVAMEDIC | Navamedic Q1 2025: Strong start of the year and well-positioned for future growth | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 29 Apr 2025 17:35 CEST |
NAVAMEDIC | Navamedic ASA: Imdur® distribution agreement extended to 2032 | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 28 Apr 2025 16:44 CEST |
NAVAMEDIC | Navamedic ASA: Conclusion received from the Norwegian Financial Supervisory Authority | 20103015 Pharmaceuticals | Inside information |
| 28 Apr 2025 12:06 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2025 1st quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Apr 2025 08:50 CEST |
NAVAMEDIC | Navamedic ASA: Navamedic has entered into an agreement in principle with Observe Medical ASA to reduce the loan receivable by 50% | 20103015 Pharmaceuticals | Inside information |
| 01 Apr 2025 15:00 CEST |
NAVAMEDIC | Navamedic Welcomes CHMP's Positive Review of Mysimba's Cardiovascular Safety | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 28 Mar 2025 14:25 CET |
NAVAMEDIC | Navamedic ASA: Letter received from the Norwegian Financial Supervisory Authority | 20103015 Pharmaceuticals | Inside information |
| 19 Mar 2025 15:52 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 10 Mar 2025 17:00 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 28 Feb 2025 16:13 CET |
NAVAMEDIC | Flaggemelding Navamedic (NAVA) | 20103015 Pharmaceuticals | Flagging |
| 14 Feb 2025 16:47 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 12 Feb 2025 07:00 CET |
NAVAMEDIC | Navamedic Q4 og 2024: Et år med stabil utvikling og investeringer for videre vekst | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 12 Feb 2025 07:00 CET |
NAVAMEDIC | Navamedic Q4 and Full Year 2024: Continued growth in a year with investments in new growth initiatives | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 10 Feb 2025 11:00 CET |
NAVAMEDIC | Navamedic ASA: Invitation to 2024 4th quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Dec 2024 19:37 CET |
NAVAMEDIC | Navamedic ASA - Mandatory notification of trade by primary insider | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 04 Dec 2024 16:28 CET |
NAVAMEDIC | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Nov 2024 12:01 CET |
NAVAMEDIC | Major shareholder disclosure in Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 19 Nov 2024 10:43 CET |
NAVAMEDIC | Flaggemelding Navamedic (NAVA) | 20103015 Pharmaceuticals | Flagging |
| 15 Nov 2024 13:00 CET |
NAVAMEDIC | Navamedic ASA: Amendments to loan agreements with Observe Medical ASA | 20103015 Pharmaceuticals | Inside information |
| 06 Nov 2024 13:52 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 06 Nov 2024 09:10 CET |
NAVAMEDIC | Navamedic launches Eroxon[®] in Finland | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 31 Oct 2024 07:00 CET |
NAVAMEDIC | Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 31 Oct 2024 07:00 CET |
NAVAMEDIC | Navamedic 3. kvartal 2024: Fortsatt solide resultater i et kvartal som er preget av at markedet er syklisk av natur | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 28 Oct 2024 09:09 CET |
NAVAMEDIC | Navamedic ASA: Invitation to 2024 3rd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Oct 2024 13:57 CEST |
NAVAMEDIC | Navamedic wins joint Nordic antibiotics tender | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 19 Sep 2024 08:24 CEST |
NAVAMEDIC | Navamedic ASA - Registration of share capital increase | 20103015 Pharmaceuticals | Total number of voting rights and capital |
| 12 Sep 2024 12:00 CEST |
NAVAMEDIC | Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson's Disease | 20103015 Pharmaceuticals | Ikke-informasjonspliktige pressemeldinger |
| 09 Sep 2024 16:47 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notification of trade by primary insider | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 09 Sep 2024 16:03 CEST |
NAVAMEDIC | NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Aug 2024 17:20 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 20 Aug 2024 17:31 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notice of trade | 20103015 Pharmaceuticals | Meldepliktig handel for primærinnsidere |
| 16 Aug 2024 07:00 CEST |
NAVAMEDIC | Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 16 Aug 2024 07:00 CEST |
NAVAMEDIC | Navamedic 2. kvartal og H1 2024: Den stabile veksten fortsetter, understøttet av ny lisensavtale | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 14 Aug 2024 12:22 CEST |
NAVAMEDIC | Major shareholder disclosure in Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 13 Aug 2024 15:36 CEST |
NAVAMEDIC | Major shareholder disclosure in Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 12 Aug 2024 10:00 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2024 2nd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Jul 2024 20:59 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 24 Jun 2024 16:19 CEST |
NAVAMEDIC | Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe | 20103015 Pharmaceuticals | Inside information |
| 04 Jun 2024 10:18 CEST |
NAVAMEDIC | Navamedic ASA: Minutes of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 May 2024 09:00 CEST |
NAVAMEDIC | Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 14 May 2024 14:10 CEST |
NAVAMEDIC | Navamedic ASA: Notice of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 06 May 2024 11:00 CEST |
NAVAMEDIC | Navamedic ASA: Broad launch for Eroxon® in Sweden today | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 06 May 2024 11:00 CEST |
NAVAMEDIC | Första behandlingen mot erektionsproblem utan recept lanseras på svenska apotek | 20103015 Pharmaceuticals | Ikke-informasjonspliktige pressemeldinger |
| 30 Apr 2024 17:45 CEST |
NAVAMEDIC | Navamedic ASA: Annual Report 2023 | 20103015 Pharmaceuticals | Annual financial and audit Reports |